RGEN vs DHR vs A Stock Comparison

Repligen, Danaher and Agilent Technologies Prices as of Oct 23, 2026 Peers: Industry group
RGEN Repligen Corp
$176.93 -4.1% 1M +7.1% 1Y
Market cap
$10.14B
P/E
244.2x
Revenue (TTM)
$785.10M
Div. yield
–
Life Sciences Tools Healthcare
3 wins
DHR Danaher Corp /De/
$230.44 +3.9% 1M +3.5% 1Y
Market cap
$164.19B
P/E
41.0x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
A Agilent Technologies, Inc.
$173.05 +4.7% 1M +17.4% 1Y
Market cap
$49.59B
P/E
34.4x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
5 wins

Head to Head

11 decided of 12

Agilent Technologies leads on 5 of the 12 questions below (Agilent Technologies 5, Danaher 3, Repligen 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRGENDHRALeader
Larger companyMarket capitalisation $10.14B $164.19B $49.59B DHR
Cheaper on earningsLower P/E, profitable companies only 244.2x 41.0x 34.4x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 91.2x 25.5x 26.5x DHR
Faster revenue growthRevenue growth, trailing twelve months +16.5% +4.6% +8.6% RGEN
More profitableNet margin, trailing twelve months 5.3% 15.9% 19.5% A
Better return on capitalReturn on invested capital 1.9% 5.7% 13.1% A
Less leveragedLower net debt / EBITDA -1.6x 2.9x 1.1x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +7.1% +3.5% +17.4% A
Better 5-year returnAnnualised price return, 5 years -8.4%/yr -6.0%/yr +1.8%/yr A
Less volatileAnnualised volatility, 1 year 46.3% 30.6% 32.3% DHR
Higher overall scoreMean of the five percentile scores vs peers 66/100 60/100 62/100 RGEN

Percentile Scorecard

RGENDHRA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRGENDHRA
Valuation 53 #108 of 228 67 #75 of 228 57 #98 of 228
Growth 56 #98 of 222 20 #178 of 222 36 #143 of 222
Profitability 70 #63 of 210 88 #27 of 210 91 #20 of 210
Financial Health 80 #49 of 241 46 #131 of 241 55 #108 of 241
Shareholder Returns 70 #42 of 138 77 #32 of 138 69 #43 of 138
Overall 66 60 62
  • RGEN ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • A ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRGENDHRASPY
1 month -4.1%+3.9%+4.7% -1.0%
3 months +34.1%+20.3%+24.9% +2.9%
6 months +50.5%+30.0%+49.8% +6.4%
Year to date +8.0%+0.7%+27.2% +11.4%
1 year +7.1%+3.5%+17.4% +13.1%
3 years +26.6%+17.1%+63.8% +79.4%
3 years, per year +8.2%+5.4%+17.9% +21.5%
5 years -35.7%-26.5%+9.5% +67.7%
5 years, per year -8.4%-6.0%+1.8% +10.9%
10 years +504.9%+187.4%+279.7% +255.2%
10 years, per year +19.7%+11.1%+14.3% +13.5%

Risk

MeasureRGENDHRASPY
Volatility, 1Y 46.3%30.6%32.3% 12.7%
Downside volatility, 1Y 46.9%31.7%27.5% 12.7%
Beta vs S&P 500, 1Y 1.180.440.86 1.00
Return / volatility, 1Y 0.150.110.54 1.03
Max drawdown, 5Y -66.2%-50.8%-39.6% -25.4%
From 52-week high -9.1%-4.8%-2.6% -2.5%
52-week high $194.57$242.05$177.72 $779.14
52-week low $102.87$161.91$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRGENDHRA
P/E now vs peer median 240.3xmedian 30.7x 40.6xmedian 30.7x 33.9xmedian 30.7x
P/S now vs peer median 12.7xmedian 3.0x 6.5xmedian 3.0x 6.6xmedian 3.0x
EV/EBITDA now vs peer median 60.5xmedian 17.7x 24.0xmedian 17.7x 26.7xmedian 17.7x
P/FCF now vs peer median 89.2xmedian 23.7x 29.6xmedian 23.7x 38.5xmedian 23.7x
P/B now vs peer median 4.7xmedian 2.4x 3.1xmedian 2.4x 6.6xmedian 2.4x
PEG now vs peer median -7.90median 0.96 -3.24median 0.96 3.45median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRGENDHRA
Revenue $785.10M $25.11B $7.37B
Gross profit $422.67M $14.69B $3.97B
Operating income $64.61M $5.13B $1.64B
Net income $41.54M $4.00B $1.44B
Free cash flow $111.97M $5.47B $1.27B
R&D $56.17M $1.62B $485.00M
EPS (diluted) $0.73 $5.66 $5.09
Cash & equivalents $606.78M $4.35B $1.76B
Total debt $551.05M $26.56B $3.95B
Shares (diluted) 56.64M 707.60M 283.00M
Enterprise value $7.03B $148.00B $42.48B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRGENDHRA
P/E 240.3x 40.6x 33.9x
P/FCF 89.2x 29.6x 38.5x
P/Operating cash flow 74.0x 24.4x 30.3x
P/S 12.7x 6.5x 6.6x
P/B 4.7x 3.1x 6.6x
P/Tangible book 5.7x 5.2x 7.6x
EV/EBITDA 60.5x 24.0x 26.7x
EV/EBIT 150.5x 35.9x 31.1x
EV/Revenue 12.4x 7.3x 6.9x
EV/FCF 86.9x 33.7x 40.2x
EV/Operating cash flow 72.1x 27.8x 31.7x
PEG (3Y EPS CAGR) -7.90 -3.24 3.45

Growth

14 metrics
MetricRGENDHRA
Revenue growth (1Y) 16.5% 4.6% 8.6%
Revenue CAGR (3Y) 3.3% -0.5% 1.8%
Gross profit growth (1Y) 40.6% 2.6% 11.2%
Gross profit CAGR (3Y) 4.2% -0.9% 3.7%
Operating income growth (1Y) 370.8% 16.1% 13.5%
Operating income CAGR (3Y) -21.7% -7.1% 5.1%
Net income growth (1Y) 400.4% 17.3% 18.0%
Net income CAGR (3Y) -30.6% -14.3% 8.3%
EPS growth (1Y) 399.7% 19.2% 18.9%
EPS CAGR (3Y) -30.4% -12.5% 9.8%
Operating cash flow growth (1Y) 2.1% 7.6% 7.6%
Operating cash flow CAGR (3Y) -3.2% -7.6% -1.9%
Free cash flow growth (1Y) 2.8% 12.4% 16.5%
Free cash flow CAGR (3Y) 3.9% -9.0% -3.7%

Profitability

14 metrics
MetricRGENDHRA
Gross margin 53.8% 58.5% 53.8%
EBITDA margin 20.5% 30.5% 25.9%
Operating margin 8.2% 20.4% 22.2%
Pretax margin 6.6% 19.0% 22.5%
Net margin 5.3% 15.9% 19.5%
FCF margin 14.3% 21.8% 17.2%
Operating cash flow margin 17.2% 26.4% 21.8%
Return on equity 2.0% 7.6% 19.9%
Return on assets 1.4% 4.5% 10.7%
Return on invested capital 1.9% 5.7% 13.1%
Return on capital employed 2.3% 6.4% 14.6%
Asset turnover 0.3x 0.3x 0.5x
Cash conversion (OCF / net income) 3.2x 1.7x 1.1x
Stock comp / revenue 4.2% 1.2% 1.8%

Financial Health

11 metrics
MetricRGENDHRA
Debt / assets 18.7% 28.8% 28.3%
Debt / equity 0.3x 0.5x 0.5x
Net debt / EBITDA -1.6x 2.9x 1.1x
Debt / FCF 4.9x 4.9x 3.1x
Liabilities / assets 28.4% 43.1% 47.3%
Equity / assets 71.6% 56.9% 52.7%
Interest coverage 2.9x 17.6x 15.5x
Current ratio 9.1x 1.7x 2.1x
Quick ratio 7.3x 1.0x 1.4x
Cash ratio 6.1x 0.5x 0.8x
Altman Z-score 8.14 3.70 5.75

Shareholder Returns

7 metrics
MetricRGENDHRA
Dividend yield – 0.7% 0.6%
Net buyback yield 0.0% 1.8% 0.6%
Shareholder yield 0.0% 2.5% 1.2%
Payout ratio (earnings) – – 19.9%
Payout ratio (FCF) – – 22.6%
Dividend growth (1Y) – – 2.1%
Dividend CAGR (3Y) – – 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRGENDHRA
Forward P/E 91.2xFY2026 25.5xFY2026 26.5xFY2026
EPS, next fiscal year $1.94FY2026 $9.03FY2026 $6.54FY2026
EPS growth, next FY +13.5%FY2026 +15.8%FY2026 +17.0%FY2026
EPS growth, the year after +29.4% +8.9% +0.6%
Revenue, next fiscal year $772.56MFY2026 $27.12BFY2026 $7.87BFY2026
Revenue growth, next FY +4.6%FY2026 +10.4%FY2026 +15.3%FY2026
Revenue growth, the year after +35.2% -1.6% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRGENDHRA
Held by institutions 100.0% 81.9% 92.6%
Institutions holding 482 2,115 1,122
Change in shares held, QoQ +1.2% +1.1% +3.2%
Institutions buying 272 837 599
Institutions selling 141 1,015 350
Buyers to sellers 1.93 0.82 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RGENDHRA
RGEN 1.00 0.63 0.61
DHR 0.63 1.00 0.60
A 0.61 0.60 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RGEN, DHR and A?

Danaher (DHR) is the largest by market capitalisation: Repligen (RGEN) $10.14B, Danaher (DHR) $164.19B, Agilent Technologies (A) $49.59B.

Which stock is cheaper, RGEN, DHR and A?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Repligen (RGEN) 244.2x, Danaher (DHR) 41.0x, Agilent Technologies (A) 34.4x). On next year's consensus earnings, Danaher (DHR) is cheapest (Repligen (RGEN) 91.2x, Danaher (DHR) 25.5x, Agilent Technologies (A) 26.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Repligen (RGEN) +16.5%, Danaher (DHR) +4.6%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Repligen (RGEN) 5.3%, Danaher (DHR) 15.9%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Repligen (RGEN) 1.9%, Danaher (DHR) 5.7%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Repligen (RGEN) +7.1%, Danaher (DHR) +3.5%, Agilent Technologies (A) +17.4%. Over five years, Agilent Technologies (A) compounded fastest (Repligen (RGEN) -8.4%/yr, Danaher (DHR) -6.0%/yr, Agilent Technologies (A) +1.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Repligen (RGEN) 0.00%, Danaher (DHR) 0.00%, Agilent Technologies (A) 0.01%. Repligen (RGEN) and Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Repligen (RGEN) 46.3%, Danaher (DHR) 30.6%, Agilent Technologies (A) 32.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RGEN, DHR and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.